Evidence mapPaperPMID 40423799Full record

ArticleCellular and molecular life sciences : CMLS2025

IGFBP5 promotes EndoMT and renal fibrosis through H3K18 lactylation in diabetic nephropathy.

Xiaofang Hu, Wei Chen, Ming Yang, Mengwei Li, Xiangyi Li, Shaxi Ouyang

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Regulated cell death: a multidimensional regulatory network in the pathogenesis of renal fibrosis.Apoptosis : an international journal on programmed cell death · 2026
    Review
  6. Review
  7. Review
  8. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Lactate Metabolism and Protein Lactylation in Diabetic Kidney Disease: A Narrative Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaofang HuHunan Normal University Health Science Center, Changsha, 410013, Hunan, People's Republic of China.
Wei ChenHunan Normal University Health Science Center, Changsha, 410013, Hunan, People's Republic of China.
Ming YangDepartment of Nephrology, Zhuzhou Central Hospital, Zhuzhou, 412007, People's Republic of China.
Mengwei LiHunan Normal University Health Science Center, Changsha, 410013, Hunan, People's Republic of China.
Xiangyi LiDepartment of Nephrology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61 Jie-Fang West Road, Fu-Rong District, Changsha, 410005, Hunan, People's Republic of China.
Shaxi OuyangDepartment of Nephrology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61 Jie-Fang West Road, Fu-Rong District, Changsha, 410005, Hunan, People's Republic of China. shaxiouyang@163.com.ORCID http://orcid.org/0000-0003-2319-5640

Funding

Natural Science Foundation of Hunan Province 2024JJ9280
6 · The paper itself

Abstract

objectiveDiabetic nephropathy (DN) is an important complication in diabetic patients that severely impacts their quality of life and life expectancy. Although metabolic and inflammatory responses induced by hyperglycemia are considered the primary pathogenic factors of DN, the specific molecular mechanisms involved remain unclear. Here, we investigated the role of insulin-like growth factor-binding protein 5 (IGFBP5) in DN using in vitro cell experiments and mouse models.

methodsWe assessed the effects of high-glucose conditions on IGFBP5 expression in glomerular endothelial cells and evaluated its regulatory effects on glycolysis, NLRP3 inflammasome activation, endothelial‒mesenchymal transition (EndoMT), and histone lactylation via the suppression of IGFBP5. Furthermore, we evaluated the effects of IGFBP5 on renal fibrosis and confirmed its regulatory mechanisms in DN model mice.

resultsKnockdown of IGFBP5 inhibited high glucose-induced EndoMT in glomerular endothelial cells, which could also be suppressed by the NLRP3 inflammasome inhibitor MCC950. In addition, silencing of IGFBP5 decreased glycolytic activity and histone lactylation, thereby inhibiting the activation of the NLRP3 inflammasome and EndoMT. Furthermore, in mouse models of DN, IGFBP5 knockdown alleviated renal fibrosis and reduced glycolysis, histone lactylation, NLRP3 inflammasome activation and EndoMT.

conclusionsIGFBP5 promotes NLRP3 inflammasome-induced EndoMT and renal fibrosis by regulating glycolysis-mediated histone lactylation, accelerating the progression of DN. These findings provide a new potential therapeutic target for DN.

Indexed as

Diabetic NephropathiesEpithelial-Mesenchymal TransitionHistonesInsulin-Like Growth Factor Binding Protein 5KidneyAnimalsDiabetes Mellitus, ExperimentalDisease Models, AnimalEndothelial CellsFibrosisGlucoseGlycolysisHumansInflammasomesMaleMiceGlucoseHistonesInflammasomesInsulin-Like Growth Factor Binding Protein 5NLR Family, Pyrin Domain-Containing 3 Protein2-DGDiabetic kidney diseaseGEnCsH3K18 laMesenchymal phenotype

Identifiers

PMID40423799
PMCPMC12116956

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.